Overall: AdvaMed believes that the current issues in MDR/IVDR implementation are best addressed through application of both short-term measures, to be implemented as soon as possible, ideally this year, in combination with longer-term measures, as outlined in these two papers: medtech-europe_mdr_ivdr_leaflet_four-urgent-targeted-measures-1.pdf; joint-discussion-paper-on-future-governance-of-medical-technologies.pdf.
ADV
AdvaMed
Trade union · United States · EU Transparency Register 822761899136-02
2
positions filed
in the 665 files tracked
2
legislative files
of 665 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1518 trade and business associations on this site, they rank #987 by legislative files engaged, a count of participation, not a measure of influence.
0.2
declared lobbying FTE
self-declared
< €10K
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2025
in the register since
- Register category
- Trade and business associations
- Registered as
- Advanced Medical Technology Assoc. (AdvaMed)
- Head office
- Washington, DC, United states
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track AdvaMed in PolicySpeak: request access →
Work at AdvaMed? so we know who speaks for it.
Their record over time
AdvaMed filed 2 positions between 18 Jan 2023 and 4 Oct 2025, across 2 of the 665 legislative files tracked here, attaching a full position paper 1 time.
2023 · 1 filed2025 · 1 filed
What they argued
The Advanced Medical Technology Association (AdvaMed) would like to highlight the utmost importance of ensuring the continuity of patient care in Europe and underscores the comments submitted by MedTech Europe, which highlight the importance for adoption of this legislative proposal as swiftly as possible, as follows -- MedTech Europe takes note of the European Commission's proposal to amend the transitional…
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put AdvaMed next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 16.
Is this your organization?
Everything on this page comes from AdvaMed’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.